Polypeptides, polynucleotides and uses thereof

Details Polypeptides, polynucleotides and uses thereof Polypeptides, polynucleotides and uses thereof

2007-10-30

2010-10-12

Rawlings, Stephen L (Department: 1643)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C435S325000, C536S023100, C536S023500

Reexamination Certificate

active

07811789

ABSTRACT:
A recombinant polynucleotide encoding migrating stimulating factor (MSF) or variants or fragments or derivatives or fusions thereof or fusions of said variants or fragments or derivatives. Reagents are disclosed which can distinguish MSF and fibronectin, and which can distinguish polynucleotides which encode MSF or fibronectin. These reagents are believed to be useful in, for example, diagnosing cancer. MSF or variants or fragments or derivatives or fusions thereof, or fusions of said variants or fusions or derivatives, are useful in modulating cell migration and in wound healing.

REFERENCES:
patent: 4980279 (1990-12-01), Peters et al.
patent: 5049658 (1991-09-01), Kimizuka et al.
patent: 5124155 (1992-06-01), Reich
patent: 5300630 (1994-04-01), Matsuura et al.
patent: 5571679 (1996-11-01), Sekiguchi et al.
patent: 5629291 (1997-05-01), Ruoslahti et al.
patent: 5830700 (1998-11-01), Irani
patent: 0 207 751 (1986-06-01), None
patent: 0 344 134 (1989-05-01), None
patent: 5310592 (1993-11-01), None
patent: 8291059 (1996-11-01), None
patent: WO 90/00567 (1990-01-01), None
patent: WO 94/16085 (1994-07-01), None
patent: WO 99/02674 (1999-01-01), None
patent: WO 99/31233 (1999-06-01), None
Bowie et al. (Science 1990; 257: 1306-1310).
Luque et al. (Biochemistry. Nov. 19, 2002; 41 (46): 13663-13671).
Vucic et al. (J. Biol. Chem. Dec. 18, 1998; 273 (51): 33915-33921).
Takada et al. (Mol. Endocrinol. 2000; 14 (5): 733-740).
Guo et al. (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101 (25): 9205-9210).
Amalfitano A , et al. Cur Gene Ther. 2002; 2: 111-33.
Bendig MM. Genet Eng. 1988; (7): 91-127.
Benoliel AM, et al. J Cell Sci. Sep. 1997; 110 (Pt 17): 2089-97.
Bristow AF. Trends Biotechnol. Jul. 1993; 11(7): 301-5.
Burgess WH et al. J Cell Biol Nov. 1990; 111 (5 Pt 1): 2129-38.
Dean et al. Cloning and analysis of the premotor region of the human fibronectin gene; Proc. Nat.; Acad. Sci, USA, vol. 84, pp. 1876-1880, Apr. 1987.
Desimone et al. Identification and characterization of alternatively spliced fibronectin mRNAs expressed in early Zenopus embryos, SWISSPROT Database Accession Ref. FINC—XENLA, Dev. Biol. vol. 149 pp. 357-369 (1992).
Ellis et al. Antogonistic effects of TGF-61 and MSF on fibroblast migration and hyaluronic acid synthesis, Possible Implications for dermal wound healing, Journal of Cell Science, vol. 102, pp. 447-456 (1992) UK.
Genbank Accession No. AJ276395 [gi:12053816].
Grey et al. Purification of the migration stimulating factor produced by fetal and breast cancer patients fibroblasts, Proc. Natl. Acad. Sci, USA, vol. 86, pp. 2438-2422, Apr. 1989.
Guo et al., (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101(25): 9205-9210).
Gura T. Science. Nov. 7, 1997; 278 (5340): 1041-2.
Houdebine LM. J Biotechnol. May 31, 1994; 34 (3): 269-87.
Hynes et al. EMBL Data library PIR2 Accession No. S14428, 1989.
Irwin et al. Inter-and Intra-site heterogeneity in the expression of fetal-like phenotypic characteristic by gingival fibroblasts: potential significance for wound healing, Journal of Cell Science, vol. 107, pp. 1333-1346 (1994) UK.
Kornblihtt, et al. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO Sequence Database Accession No. X02761; 4:1755-1759 (1985).
Kornblihtt, et al. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO, (USA) vol. 4 pp. 1755-1759 (1985).
Kornblihtt, et al. SWISSPROT Sequence Database Accession No. P02751 (1986).
Lazar E et al. Mol Cell Biol Mar. 1988; 8 (3):1247-52.
Pandha HS et al. Cur Opin Invest Drugs. 2000; 1 (1): 122-34.
Patterson AP. Memorandum (Jan. 14, 2003); pp. 3.
Picardo et al. Detection of migration stimulating activity in wound fluid, Experimental and Molecular Pathology vol. 57, pp. 8-21 (1992).
PIRI Sequence Database (1985) Accession Ref. FNHU.
Schor et al. (1993) in Cell Behavior: Adhesion and Motility (ed G. Evans, C. Wigley & R. Warn) Society for Experimental Biology Symposium No. 47, pp. 235-251.
Schor, Fibroblast subpopulations as accelerators of tumor progression: Yhe role of migration stimulating factor, Epithelial-Mesenchymal Interactions in Cancer, 1995 pp. 273-296, Switzerland.
Schor et al., (Breast Cancer Res. 2001; 3:373-379).
Schor SL, et al., Cancer Res. Dec. 2003; 63 (24): 8827-36.
Schor et al. Characterization of migration-stimulating factor (MSF): Evidence of its role in cancer pathogenesis, Cancer Investigation vol. 8(6), pp. 665-667 (1990).
Schor et al. Fetal and cancer patient fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells, Journal of Cell Science, vol. 90, pp. 391-399 (1998) UK.
Schor et al. Fetal-like fibroblasts: their production of migration stimulating factor and role in tumor progression, Mammary Tumorigenesis and Malignant Progression, pp. 277-298, 1994.
Schor et al. Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics; Journal of Cell Science, vol. 90, pp. 401-407 (1998) UK.
Schor et al. Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implication for cancer pathogenesis, Cell Motility Factors, pp. 127-146, 1992.
Schor et al. Mechanism of action of the migration stlimulating factor produced by fetal and cancer patient fibroblasts: Effect on hyaluronic acid synthesis, In Vitro Cellular Development and Biology, vol. 25, No. 8, pp. 737-746, Aug. 1989.
Schor et al. Migration stimulating factor (MSF): Its structure mode of action and possible functional health and disease; The Society of Experimental Biology 1993, pp. 235-251, UK.
Schor et al. Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma, Int. J. Cancer, vol. 59, pp. 25-32 (1994).
Skolnick J, et al. Trends Biotechnol Jan. 2000; 18 (1): 34-9.
Picardo et al. Migration stimulating activity in serum of breast cancer patients, The Lancet, vol. 337, pp. 130-134, Jan. 19, 1991.
Takada et al., (Mol. Endocrinol. 2000; 14(5): 733-740).
UniProtKB Entry No. P02751 (25 pages).
Verma IM et al. Nature. Sep. 18, 1997; 389 (6648): 239-42.
Ward AM. Developmental Oncol. 1985; 21: 91-106.
Macsween , R. N. M. et al. InMuir's textbook of Pathology 13thed., “Healing of Skin Wounds: Healing by Primary Intention (Primary Union)”, 1992, pp. 158-159, Edward Arnold, London.
Schor et al. Fetal and cancer patient fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells, Journal of Cell Science, vol. 90, pp. 391-399 (1988).
Schor et al. Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics; Journal of Cell Science, vol. 90, pp. 401-407 (1988) UK.

Affiliated with

Also associated with

Rating

Polypeptides, polynucleotides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptides, polynucleotides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides, polynucleotides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4236021